Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 260

The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Pang, Kun, Shi, Zhen-Duo, Wei, Liu-Ya, Dong, Yang, Ma, Yu-Yang, Wang, Wei, Wang, Guang-Yue, Cao, Ming-Yang, Dong, Jia-Jun, Chen, Yu-Ang, Zhang, Peng, Hao, Lin, Xu, Hao, Pan, Deng, Chen, Zhe-Sheng, Han, Cong-Hui · 2023 · Drug Resistance Updates

Abstract

The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and promote the immune escape of tumor cells. Therefore, immune checkpoint blockade targeting PD-1/PD-L1 is a reliable tumor therapy with remarkable efficacy. However, the main challenges of this therapy are low response rate and acquired resistance, so that the outcomes of this therapy are usually unsatisfactory. This review begins with the description of biological structure of the PD-1/PD-L1 immune checkpoint and its role in a variety of cells. Subsequently, the therapeutic effects of immune checkpoint blockers (PD-1 / PD-L1 inhibitors) in various tumors were introduced and analyzed, and the reasons affecting the function of PD-1/PD-L1 were systematically analyzed. Then, we focused on analyzing, sorting out and introducing the possible underlying mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade including abnormal expression of PD-1/PD-L1 and some factors, immune-related pathways, tumor immune microenvironment, and T cell dysfunction and others. Finally, promising therapeutic strategies to sensitize the resistant patients with PD-1/PD-L1 blockade treatment were described. This review is aimed at providing guidance for the treatment of various tumors, and highlighting the drug resistance mechanisms to offer directions for future tumor treatment and improvement of patient prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drup.2022.100907

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 260

Metadata

Authors
Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., Zhang, P., Hao, L., Xu, H., Pan, D., Chen, Z.-S., & Han, C.-H.
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2023-01
Volume
66
Pages
100907
ISSN
1368-7646 (ISSN-L)
OpenAlex
W4310424284
Cited by
260
References
164
FWCI
17.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.